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Donna M Wilcock1 and W Sue T Griffin2,3*
Abstract
Down syndrome (DS) is the result of triplication of chromosome 21 (trisomy 21) and is the prevailing cause of
mental retardation. In addition to the mental deficiencies and physical anomalies noted at birth, triplication of
chromosome 21 gene products results in the neuropathological and cognitive changes of Alzheimer’s disease (AD).
Mapping of the gene that encodes the precursor protein (APP) of the β-amyloid (Aβ) present in the Aβ plaques in
both AD and DS to chromosome 21 was strong evidence that this chromosome 21 gene product was a principal
neuropathogenic culprit in AD as well as DS. The discovery of neuroinflammatory changes, including dramatic
proliferation of activated glia overexpressing a chromosome 2 gene product - the pluripotent immune cytokine
interleukin-1 (IL-1) - and a chromosome 21 gene product - S100B - in the brains of fetuses, neonates, and children
with DS opened the possibility that early events in Alzheimer pathogenesis were driven by cytokines. The specific
chromosome 21 gene products and the complexity of the mechanisms they engender that give rise to the
neuroinflammatory responses noted in fetal development of the DS brain and their potential as accelerators of
Alzheimer neuropathogenesis in DS are topics of this review, particularly as they relate to development and
propagation of neuroinflammation, the consequences of which are recognized clinically and neuropathologically as
Alzheimer’s disease.
Introduction
Down syndrome (DS), trisomy 21, is the most common
chromosomal defect, with an incidence in the United
States of one per seven-hundred and thirty-three live
births [1] with the rate of spontaneous abortions among
trisomy 21 fetuses being 7-fold that among non-trisomic
fetuses. Not only is trisomy 21 the most frequent cause
of mental retardation [2,3], due to the extensive number
of chromosome 21 genes [4], there is an extremely high
incidence of congenital anomalies such as important
cardiac and gastrointestinal malformations in trisomy 21
[5]. In the brain, neuritic amyloid-β (Aβ) plaques - a
characteristic neuropathological feature of Alzheimer’s
disease (AD) - are a virtually certain finding in adults
with DS [6-8] and have been noted in some children
with DS [9]. For instance, among 12 children with DS, two
(ages 8 and 9 years) had Aβ plaques, and among those
between the ages of 35 and 45 years, all had neuritic Aβ
plaques and other AD pathologies, such as neurofibrillary
tangles and glial activation. Although the prediction of AD
neuropathological changes at middle age is reported to be
a virtual certainty in those with DS, predictions regarding
timing of the onset of dementia are less certain, with
estimates of approximately 50 to 70% of individuals with
DS developing dementia by age 60 to 70 years [10-15].
Identification and characterization of early events that
contribute to and or regulate the expression of chromo-
some 21 gene products that are triplicated in DS is vital if
we are to understand the ways in which neurodegenerative
cycles and the mechanisms they employ in promotion of
the neuropathophysiological progression of sporadic AD
and of AD in DS. Three such early events have been
reported in DS fetuses and each is related to the others as
they induce, and are induced by each other and by
cytokines subsequent to neuroinflammatory changes.
In particular, these include overexpression of two
chromosome 21 gene products - APP [16] and S100B
[17] - and the resultant overexpression of the pluripotent
neuroinflammatory cytokine IL-1 [17], which is encoded
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by chromosome 2 genes IL-1A and IL-1B [18,19]. Complex
interactions between APP, glial activation, S100B, and IL-1
include upregulation of the expression of IL-1α and β
by both APP [20] and S100B [21,22], and induction of
both APP and S100B by IL-1β [23]. Such interactions
have been shown to be elicited by multiple neural
insults, each of which is characterized by gliosis-related
neuroinflammation and risk for development of the
characteristic neuropathological changes of AD [24].
It is now more than twenty years since the report of
prominent glial activation with excessive expression of
inflammatory cytokines such as the chromosome 21
gene product S100B and the chromosome 2 gene product
IL-1 in DS fetuses, infants, children, and adults in DS,
and in AD [17,25]. Such glial activation and cytokine
overexpression occurs years before the virtually certain
appearance at middle age of the Aβ plaques in DS [14].
Accompanying reports demonstrated that IL-1 induces
the synthesis of APP in non-neural and neural cells
[21,26]; this IL-1 induction of APP was later verified in
neurons in in vitro and in vivo studies that included
evidence of IL-1 induction of S100B [23]. As evidence
that glial activation and neuronal expression of APP are
potentially self-propagating events, IL-1 and S100B both
induce microglial and astrocytic activation with over-
expression of themselves, as well as of neuronal APP
[23,27]. This idea was supported by reports from Barger
[20] and Li et al. [28] of neuronal stress-induced excessive
expression of neuronal APP and elevated release of sAPP,
which, in turn, activates microglia and induces their
overexpression of IL-1β [20]. Taken together, these reports
suggest that glial activation and resulting cytokine over-
expression contribute to APP overexpression and in so
doing may favor the appearance of Aβ plaques in children
with DS. In DS, then, it may be sufficient to merely invoke
gene load-related upregulation of neuronal APP and astro-
cytic S100B as seminal events that may drive neuronal
stress, glial activation, and DS-related neuropathological
changes characteristic of AD.
Experimental evidence supports the idea that excessive
levels of cytokines such as IL-1 and S100B are key factors
in development of the neuropathological changes of AD.
For instance in the presence of excess IL-1, whether
in brains of experimental animals or in purified rodent
neurons in cultures, APP is overexpressed [23,29]. It is
logical to assume that in situ glial activation with excess
IL-1β would favor genesis and progression of Aβ plaque
maturation [30], increases in synthesis and phosphoryl-
ation of the MAPK-p38 necessary for production of
hyperphosphorylated tau and neurofibrillary tangle for-
mation [31]. Such neuroinflammatory consequences are
consistent with the idea that any entity, which acts to
precipitate changes that lead to genesis of the same
entity, may become a self-propagating cycle and thus has
the potential to become chronic. If so, neuropathogenesis
is, at least in part, the result of self-propagating cycles
[32]. By analogy, without regard to the diversity of the
source of neuronal stress, for example, traumatic brain
injury [33], epilepsy [34-36], aging [37,38], or AIDS [39], the
downstream consequence is increased risk for develop-
ment of the neuropathological changes of AD marked by
increased expression of neuronal APP [36,40], activation
of glia, and neuroinflammatory cytokine expression [20].
Accordingly, exaggeration of such neuronal-glial interaction
due to trisomy 21 [7,24,32] would be expected to culminate
in neuropathogenic cycles that favor the progression in DS
of the neuropathological changes of AD.
The danger of chronic induction of neuroinflammation
with its manifestation of glial activation and cytokine
overexpression is related to the capacity of proinflammatory
cytokines such as IL-1β to self-propagate as they, them-
selves, activate microglia and astrocytes and further excess
expression of IL-1β. In addition to IL-1β induction of the
precursors of the principal neuropathological changes in
AD, viz., APP [23] for Aβ plaques, S100B for non-sensical
growth of dystrophic neurites in plaques [41], synthesis
and activation of MAPK-p38 for hyperphosphorylation of
tau [42,43], favors formation of neurofibrillary tangles. In
addition to favoring formation of these anomalies, IL-1β
induces the synthesis and the activity of acetylcholinester-
ase, thus favoring the breakdown of acetylcholine [28], an
important neurotransmitter in learning and memory [44],
which is known to be decreased in AD [45,46]. Similarly
devastating, excess IL-1β, as observed in DS and AD, is
associated in vitro and in vivo with decreases in the
expression of synaptophysin [31], which is a hallmark of the
synaptic loss in AD [47,48]. Such neuropathophysiological
changes would be expected to further stress neurons,
promote more neuroinflammation, and in this way create
a self-propagating cycle [40] of ever increasing neuronal
stress, dysfunction, and loss [49].
Microglia, regarded as the principal cells of the brain’s
innate immune system, were first identified as a unique
glial cell subtype in the second decade of the twentieth
century by Pio del Rio Hortega [50] and were later identi-
fied immunohistochemically using macrophage cell surface
markers [51,52]. In the second to the last decade of the
century, microglia were shown to be a primary source of
the pluripotent immune cytokine IL-1, and this together
with the astrocyte-derived neuritogenic cytokine S100B,
were held to be responsible for neuroinflammatory re-
sponses in very early stages of the development of DS, and
by analogy, perhaps in AD [17]. More recently, astrocytes
and neurons as well as oligodendrocytes and vascular
pericytes have been recognized as participants in cytokine-
related neuroinflammatory processes [53].
In AD, microglia expressing some classic activation
markers such as major histocompatibility complex
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(MHC-II) (associated with antigen presentation), CD68
(a lysosomal protein) and CD36 (a class B scavenger
receptor) are highly localized to the area immediately
surrounding an amyloid plaque or neurofibrillary tangle
[54]. While this led some to hypothesize that microglial
activation was contributing to the pathology, others
proposed they performed a beneficial function in removing
Aβ from the brain [55]. On the one hand, correlation
between the overexpression of IL-1α in such plaque-
associated microglia with plaque formation and progres-
sion from immature deposits to mature senile plaques
suggests that microglia contribute to formation and pro-
gression of Aβ plaques from deposits to mature senile
plaques [30,37,38,56]. Similarly, overexpression of IL-1α in
activated microglia adjacent to neurons bearing neurofib-
rillary tangles, as well as the role of IL-1 in promotion of
hyperphosphorylated tau [31] suggests a role for activated
glia and excess IL-1 in both the production of tangle
substrate and in the progression from paired-helical,
filamentous threads to non-neuronal, cell-shaped flames
of neurofibrillary tangles [57].
Chromosome 21 genes and neuroinflammation
Triplication of even a small region (21q22.3) on the short
arm of chromosome 21, which is referred to as the critical
region (DSCR), is sufficient to result in the DS phenotype,
prominently including mental retardation, and growth
retardation, as well as muscle, joint, and facial features
characteristic of DS [58-60]. Recognizing the importance
of an extra copy of this precise region of chromosome
21 in the pathology of DS does not lessen the potential
importance of triplication of those chromosome 21 genes,
which are located outside this region, in neuropathogenesis.
The APP gene does not map to the critical region of
chromosome 21, but more than any other gene on
chromosome 21, APP has played a seminal role in our
understanding of neuropathological changes in AD and
DS, as well as in neurological disorders that give rise to
precocious development of AD (for review please see
[49]). Steve Barger’s discovery of a role for a secreted
fragment of APP, sAPP, in synthesis and release of the
pro-neuroinflammatory cytokine IL-1 [20], together with
studies demonstrating the importance of IL-1 in promotion
of neurodegenerative events [32], underscores the import-
ance of APP, over and above its importance as the precur-
sor of the Aβ in the senile plaques characteristic of AD
and DS.
APP
Although the full significance of triplication of the APP
gene in Alzheimer pathogenesis in DS is still under investi-
gation, it is clear that there is a dramatic overexpression of
the APP gene product in fetal DS [61], which is accompan-
ied by a similarly dramatic increase in the levels of IL-1
and S100B [17], two neuroinflammation-promoting
cytokines that are known to induce the overexpression of
APP in vitro [21] and in vivo [23].
Glenner’s report of sequence homology between the
Aβ peptide derived from brains of those with AD or
with DS was the first evidence linking AD to DS, and
the APP gene to chromosome 21 [62,63]. Although the
50% increase in APP expression that would be predicted
as a consequence of gene loading (1.5×) in trisomy, may
not be sufficient to result in the characteristic patho-
physiology of DS, but, together with its induction of IL-1
and the resultant increase in APP, may be responsible, at
least in part, for the role of APP gene triplication as a
determinant of the age at onset of dementia in DS [64]
and in the development of the neuropathological changes
of AD in DS [65]. In fact, triplication of the APP gene
alone is associated with the development of early onset
AD [65-67]. Findings such as these, together with the
prominence of Aβ plaques in Alzheimer neuropathology,
led to development of the Amyloid Hypothesis [68], which
has served in many ways to expand our understanding of
how APP expression could be related to the development
not only the Aβ plaque but to a range of the neuropatho-
logical features of AD, including neurofibrillary tangles,
glial activation, and overexpression of neuroinflammatory
cytokines. However, concentration on Aβ plaques and
the Amyloid Hypothesis has to some degree led away
from the importance of overexpression of APP, itself, in
Alzheimer pathogenesis. For example, neuronal stress
imposed by a variety of neurological conditions [32],
which are associated with increased risk for development
of AD, results in overexpression of APP, release of sAPP,
glial activation, and overexpression of IL-1 for genesis of
each of the precursors of the neuropathological changes of
AD, implying that overexpression of APP starts a cascade
of events that gives rise to Aβ deposition rather than Aβ
being seminal in Alzheimer pathogenesis. An interesting
case that underscores the importance of APP overexpression
in Alzheimer pathogenesis is that of a mildly retarded
78-year-old patient with partial trisomy 21 that did not
include the APP gene sequence [69]. This patient, although
of extremely advanced age for a person with DS, especially
without the characteristic changes of AD [70], showed no
clinical signs of dementia, and magnetic resonance imaging
(MRI) 6 months before her death showed only minimal
cerebral atrophy and no temporal lobe atrophy.
BACE2
Mapping of the chromosome 21 APP gene, from which
is cleaved the Aβ fragment present in plaques in DS and
AD [61,71], together with the discovery of mutations in
chromosome 21 genes that are linked to familial AD
[71] and the virtual certain prediction of precocious
development of AD present in those with trisomy 21 [14],
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lent credence to the importance of chromosome 21 genes
in the development of AD [68]. This idea was reinforced
by the mapping of the β-amyloid cleavage enzyme 2
(BACE2) to the DS critical region of chromosome 21 [72],
which in concert with the γ-secretase complex is essential
for cleavage of Aβ 40 and 42 from APP [73,74]. On the
other hand, α-secretase, which is not encoded on chromo-
some 21, plays an important function as it cleaves extra-
cellular APP in the middle of the Aβ portion, preventing
release of Aβ [75-77], acting as a neuroprotectant [78],
and promoting activation of microglia and induction of
synthesis and release of the proinflammatory cytokine
IL-1β [20]. If BACE2 induced shedding of IL-1 receptor2
(IL-1R2) [79] acts to avail the brain of decoy receptors for
IL-1, the levels of IL-1 may be reduced and therefore
neuroinflammation responses in DS and AD dampened.
S100B
This astrocyte-derived cytokine is encoded by a chromo-
some 21 gene located in the DSCR [80]. It is markedly
elevated during normal development [81] and is elevated
throughout life in DS [25,82]. Its properties as a neurite
extension factor [83] have been suggested as a contributor
to normal growth and maintenance of neurons [84]. In
excess, as in DS and AD, S100B is associated with
marked nonsensical growth of dystrophic neuronal pro-
cesses [83,85,86], most notably in the neuritic Aβ plaques
diagnostic of AD [25,87,88].
Although S100B is important in development of the
central nervous system (CNS) [89] and is protective of
neurons from insults and promotes survival following
injury [84], elevated blood levels of S100B serve as a
marker indicative of stroke severity, survival, and pro-
gression from hemorrhage to acute thrombosis [90-92]
as well as severity of traumatic brain injury [93]. Even
seemingly minor head trauma in children and young
adults is associated with elevated blood levels of S100B
[94,95]. In addition to increased expression of S100B in
activated astrocytes in neurological conditions, systemic
diseases such as mild to severe liver disease is character-
ized by dramatic increases in astrocyte-derived S100B
expression, encephalopathy, and cognitive decline [96,97].
The role of APP and S100B in promoting neuroinflammation
The dramatic increase in the expression of APP and
S100B in DS suggests that (i) some gene product on
chromosome 21 is dramatically inducing the APP and
S100B synthesis in DS and or (ii) some chromosome 21
gene is indirectly inducing such excessive synthesis, via
induction of a gene product on another chromosome,
which, in turn, induces excessive expression of APP and
S100B. Both of these possibilities have been validated in
various cell types, including neuronal cells. For example
in the first case, S100B induces the synthesis of neuronal
APP mRNA and the production of APP [27]. In the
second case, Steve Barger provided the first evidence of
a link between neuronal stress, APP expression, and
neuroinflammation as he showed that the elevated re-
lease of the α-secretase cleaved fragment, sAPPα, which
accompanies the stress-induced increases in neuronal
expression of APP, activates microglia and induces
their expression of IL-1β [20]. Together then it may be
concluded that both a chromosome 21 gene product,
S100B [80], and a chromosome 2 gene product, IL-1β,
contribute to the elevation of APP expression in trisomy
21 to a much greater extent than that expected from gene
loading.
Finding relationships between the overexpression APP,
S100B, and IL-1β led to a series of experiments to
explore mechanisms by which activation of glia and the
resultant excess levels of neural IL-1β and S100B influence
the neuropathogenesis of AD, as well as the AD of DS
[98]. This may be especially the case as such dramatic
overexpression of APP as that in DS [61] would be
predicted to promote self-propagating cycles of more
and more production and release of neuroinflammatory
cytokines IL-1 and S100B [17] and a resultant increase
in APP. The neuronal strain of such dramatic induction
of APP synthesis [99], together with challenges imposed
by, for example Aβ plaques [40] and or the presence of
neuropathological changes such as neurofibrillary tangle
formation have been shown to be accompanied by
decreases in cellular expression of the total polyadenylated
mRNA necessary for translation of the many proteins
involved in cell functions [100].
Other lesser-studied chromosome 21 gene products and
their importance in neuroinflammatory processes
Each of the chromosome 21 genes cited below encode
(Table 1) gene products that also regulate expression of
neuroinflammatory processes, and or are regulated by
neuroinflammatory cytokines. Although their influence on
neuroinflammation and its relation to neuropathogenesis
is less studied than APP and S100B, their importance in
such pathways should not be underestimated.
CXADR
The chromosome 21 gene that encodes the receptors for
coxsackie virus and adenovirus (CXADR) acts as both a
viral receptor and as an adhesion molecule associated
with tight junctions. It is highly expressed in brain as
well as systemic secretory organs such as the pancreas,
testis, and small intestine [111]. In the absence of viral
infection CXADR expression is elevated in models of
myocardial inflammation. In view of triplication of the
CXADR gene in trisomy 21 it will be interesting to discover
whether there is a pro-inflammatory role for CXADR in
the brain similar to that in the heart [112]. This is
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particularly interesting as CXADR was recently shown
to induce stress-activated MAPK pathways in the heart
that result in increased production of IFNγ, IL-12, IL-
1β, TNFα, and IL-6 [101] as well as changes in tight
junction in cardiac vasculature [113]. Increased neural
expression of CXADR and its induction of IL-1β and
MAPK could contribute to reported MAPK-p38-dependent
hyperphosphorylation of tau and tangle formation [31,42].
ADAMTS1 and ADAMTS5
IL-1β induces synthesis of two other chromosome 21 genes
that encode two secreted proteinases of the ADAMTS
gene family (ADAMTS1 and ADAMTS5) [102,103,114]
that degrade extracellular matrix proteins. This interaction
between IL-1β and these proteinases may explain, at least
in part, the dramatic overexpression of ADAMTS1 in
DS [115]. Moreover, such excessive expression of these
proteinases in DS may contribute to degradation of
extracellular matrix proteoglycans such as aggrecan and
versican in DS [116,117].
TIAM1
The chromosome 21 gene for T-cell lymphoma invasion
and metastasis-1 (TIAM1) is a critical regulatory factor
in IL-1β-induced synthesis of NADPH oxidase [104], via
induction of guanine nucleotide exchange factor for
Rac1 [118] that contributes to the activation of Rac1 for the
activation of NADPH oxidase [119] in pancreatic β-cells.
By analogy, simultaneous excess expression of TIAM1
and IL-1 in DS brain [17,120] may contribute to the
dramatic oxidative stress in DS brain [121].
SOD1
Superoxide dismutase 1 (SOD1) is a potent endogenous
neural-relevant copper and zinc binding enzyme that is
encoded on chromosome 21 [105] and acts as a soluble
cytoplasmic and mitochondrial interspace protein that
converts superoxide radicals to molecular oxygen and
hydrogen peroxide [122]. Although the SOD1 gene is
most commonly associated with anterolateral sclerosis
(ALS) as mutation in SOD1 are linked with genetic
susceptibility to ALS [123,124]. However, overexpression
of non-mutated SOD1 in the absence of a peroxide-
detoxifying enzyme in the same cellular compartment
promotes oxidative stress [125], suggesting that the
elevation of SOD1 due to trisomy 21, if unmatched by
increases in the levels of peroxide-detoxifying enzyme,
would be detrimental [126].
IFNAR1, IFNAR2, and IFNGR2
As the genes encoding the receptors for IFNα1 and 2, and
for IFN-γ (IFNAR1, IFNAR2, and IFNGR2) are located on
chromosome 21 [106,107] and are therefore all subject to
triplication in trisomy 21. IFNAR1 and IFNAR2 respond
Table 1 A summary of the inflammation-related genes located on chromosome 21
Gene Protein Function Reference
βAPP Amyloid beta precursor protein >5 fold overexpression
in DS
Neuronal acute phase protein precursor of fragments Aβ in
Alzheimer plaques and sAPP for induction of IL-1β
[16,20,63]
BACE2 β-site APP-cleaving enzymes-2 Cleaves APP for less Aβ and increases IL-1R2, a decoy protein
for excess IL-1 capture
[79]
S100B S100 calcium binding protein astrocyte-derived
cytokine
Upregulates IL-1β and βAPP expression, released in response
to TNFα
[22,27,82]
CXADR Coxsackie virus and adenovirus receptor Activation of JNK and p38-MAPK pathways leading to
production of M1 cytokines.
[101]
ADAMTS1 ADAM metalloproteinase with thrombospondin
type 1 motif, 1
Secreted protease known to be induced by IL-1β [102]
ADAMTS5 ADAM metalloproteinase with thrombospondin
type 1 motif, 5
Secreted protease known to be induced by IL-1β and TGFβ. [103]
TIAM1 T-cell lymphoma invasion and metastasis 1 Necessary for cytokine- mediated generation of oxidative
species through NADPH oxidase.
[104]
SOD1 Superoxide dismutase 1 Scavenges superoxide radicals producing H2O2 and O2. [105]
IFNAR2 Interferon α, β, and ω receptor 2 Activates JAK/STAT mediated anti-inflammatory pathway [106,107]
IFNAR1 Interferon α, β, and ω receptor 1 Activates JAK/STAT mediated anti-inflammatory pathway [106]
IFNGR2 Interferon γ receptor 2 Activates JAK/STAT mediated anti-inflammatory pathway [107]
RIPK4 Receptor-interacting serine-threonine kinase 4 Necessary for signaling through TNFR1 [108]
CBS Cystathione-β-synthase Catalyzes production of hydrogen sulfide (H2S) bimodal
regulation of inflammation
[109]
PRMT2 Protein arginine methyltransferase 2 Blocks the actions of NFκB in the nucleus [110]
Aβ β-amyloid, APP precursor protein for β-amyloid, IL interleukin, MAPK mitogen-activated protein kinase, TNF tumor necrosis factor, TGF transforming growth
factor, JAK/STAT Janus kinase signal transducer and activator of transcription, TNFR tumor necrosis factor receptor, NFκB Nuclear factor-kappa B.
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to IFNα, β, or γ and, upon ligand binding, activate the
signaling pathway for induction of proinflammatory cyto-
kines, including IL-1β, TNFα, and IL-6 expression [127].
IFNGR2 uses the same signaling pathway but uniquely
responds to IFNγ. In the trisomy 16 mouse model of DS,
both the IFNGR2 and IFNAR2 are triplicated. Studies in
these mice, which develop significant pathology in utero
and rarely survive to birth, show that treatment of trisomy
16 fetuses with anti-IFN IgG improves the mouse pheno-
type, suggesting that the triplication of the IFN receptors
significantly contributes to the lethal pathology present in
these mice [128]. Furthermore, a partial knockout of
IFNAR2 and IFNGR2 improves growth and viability of
cultured neurons derived from trisomy 16 mouse fetuses
[129]. Therefore, the expected hyper-responsiveness to
IFN in individuals with DS may contribute to the elevated
inflammatory profile in the brain as well as systemically.
RIPK4
Receptor-interacting serine-threonine kinase 4 (RIPK4) is a
protein kinase involved in multiple cell signaling pathways.
One of these pathways is the signaling pathway for the
activation of NFκB [130,131], which is important in pro-
moting proinflammatory cytokines such as TNFα [132]. In
addition, RIPK4 is involved in the signaling cascade of the
TNFα receptor TNFR1 [108]. It is important to note that
TNFR1 is most heavily implicated in the toxic effects of
TNFα, suggesting that overexpression of RIPK4 increases
responsiveness of TNFR1 to TNFα, exacerbating the
effects of TNFR1.
CBS
The chromosome 21 gene product cystathionine beta
synthase (CBS) [109] is a cytosolic enzyme that catalyzes
the desulfhydration of cysteine for production of hydrogen
sulfide, which is now recognized as an atypical cellular
messenger that is important in both normal [133] and
abnormal cellular functions [134]. Hydrogen sulfide is
a complicated signaling molecule with an apparent
bimodal action on inflammation, in that low levels
appear to be anti-inflammatory, while high levels appear
to exacerbate neuroinflammatory processes (for review
please see [135,136]). Overexpression of CBS in trisomy
21 and its relation to development of AD in DS is, at
present, unknown.
PRMT2
The enzyme, protein arginine methyltransferase 2 (PRMT2),
facilitates the methylation of arginine necessary for regula-
tion of the JAK/STAT signaling pathway, which leads to
elevation of expression of neuroinflammatory cytokines
IFNγ, IFNα, and IL-6 [137] and via inhibition of NFκB
may promote [110] apoptosis. Importantly, degradation of
proteins containing methylated arginine results in the
production of asymmetric dimethylarginine (ADMA) [138],
inhibition of nitric oxide synthase activity, and decreased
levels of nitric oxide (NO) [139]. If there is an increase in
tissue levels of ADMA in DS brain, as there is in the
plasma of DS patients with pulmonary hypertension
[140], brain levels of NO may be decreased, the JAK-
STAT pathway increased, and changes occur toward the
inflammatory state of microglia.
Summary
The principal conclusion one may draw from information
presented here regarding the influence of triplication of
chromosome 21 genes on neuropathogenesis and develop-
ment of the clinical and neuropathological manifestations
of AD and AD in DS is that many chromosome 21 genes
upregulate classical neural immune responses of activated
microglia, which are now classified according to systemic
immune macrophage profiles as either classical M1 re-
sponses that favor overexpression of pro-inflammatory cyto-
kines, or alternative M2 responses that favor overexpression
of anti-inflammatory cytokines. As so many chromosome
21 genes are primarily associated with M1, that is, pro-
inflammatory responses, we propose that M1 is the
principle glial activation state that will be observed in
the DS brain. This is commonsensical as, for example in





Figure 1 Schematic highlighting the importance of
inflammation-associated genes in the promotion of Alzheimer
neuropathogenesis in trisomy 21. Chromosome 21 genes
triplicated in trisomy 21 activate microglia with overexpression and
release of proinflammatory cytokines, especially IL-1β, which, in turn,
induces further increases in precursor protein for β-amyloid (APP),
favoring β-amyloid (Aβ) plaque deposition, and in mitogen-activated
protein kinase (MAPK)-p38-dependent phosphorylation and
production of phosphorylated tau, favoring neurofibrillary tangle
formation, and through nuclear factor κB (NFκB) activity such
changes sustain neuroinflammatory responses and consequent
neuropathological change.
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receptor genes IFNAR1, IFNAR2 and IFNGR2 is associated
with enhancement of interferon signaling and TIAM1,
SOD1, and PRMT2 are associated with increases in oxida-
tive stresses, and S100B induces expression of APP as well
as IL-1α and β. Moreover, in brains of fetuses, neonates,
children, and adults with DS, astrocytes are activated and
express excess levels of S100B adjacent to activated micro-
glia overexpressing IL-1α and neurons overexpressing
APP. These findings, together with triplication of the
βAPP gene in DS and experimental evidence of neuronal
stress-induced increases in βAPP expression and parallel
secretion of sAPP for resultant activation of microglia,
evidenced by increases in oxidative markers and over-
expression and release of IL-1β, suggest that triplication
of chromosome 21 genes, perhaps especially βAPP, may
account for most of the very early neuroinflammatory
and oxidative changes in DS. By analogy, the neuronal
stress triggered by the many risk factors that favor develop-
ment of AD, manifested as neuronal overexpression of APP
and release of sAPP, may be prime in inducing the dramatic
neuroinflammatory responses that then result in a self-
amplifying cycle (Figure 1) of increasing neuropathological
changes, including neuronal stress, neuroinflammation, and
synthesis of the precursors giving rise to formation of the
Aβ plaques and neurofibrillary tangles diagnostic of AD.
Relative to other causative factors in individuals at
increased risk for development of AD - the small popu-
lation of individuals with mutations in Aβ-associated
genes - trisomy 21 represents the population (one in
every seven-hundred and thirty-three live births) with
the highest incidence of AD, suggesting that greater
attention should be given to investigating DS pathogenesis
as it relates to sporadic AD. Such studies could well be
directed toward not only discovery of basic molecular
mechanisms driven by chromosome 21 gene products but
also toward development of rational therapeutic approaches
to treatments that may delay onset or slow the progression
of AD, thus preserving cognitive functions not only in DS
but also in AD itself.
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